Summary
Zoetis Inc. announced on January 5, 2016, the signing of a business transfer agreement to divest its manufacturing site in Haridwar, India, along with a portfolio of associated generic products. These divested products, including medicated feed additives, anti-infectives, parasiticides, and nutritionals, were primarily sold within the Indian market and are described as lower-revenue and lower-margin. The divestment is a strategic move aligned with Zoetis's broader operational efficiency program initiated in May 2015, which aims to streamline operations, optimize resource allocation, and drive long-term profitable growth. This transaction, expected to close in the first quarter of 2016, will result in Zoetis receiving approximately $29 million in cash. The company has stated that the transaction is not material to its overall financial standing, underscoring its focus on optimizing its product portfolio and operational footprint.
Key Highlights
- 1Zoetis is divesting its manufacturing facility in Haridwar, India.
- 2The divestment includes a portfolio of generic products primarily sold in India (medicated feed additives, anti-infectives, parasiticides, nutritionals).
- 3The transaction is part of Zoetis's ongoing operational efficiency program to reduce complexity and optimize resource allocation.
- 4Zoetis will receive approximately $29 million in cash from the sale.
- 5The divested products are characterized as lower-revenue and lower-margin, aligning with the program's goal to improve profitability.
- 6The transaction is not considered material to Zoetis Inc.
- 7Completion of the transaction is anticipated in the first quarter of 2016.